You just read:

FDA Approves Praluent® (alirocumab) to Prevent Heart Attack, Stroke and Unstable Angina Requiring Hospitalization

News provided by

Regeneron Pharmaceuticals, Inc.

Apr 26, 2019, 19:19 ET